Mixing compatibility · Reference
Can you mix two peptides in one syringe?
Say you've got two vials on the counter and you're wondering if they can share one syringe. Fair question — and the honest headline is that for most peptide pairs, nobody actually knows. No one has studied whether they hold up together in the same vial, so this tool's default verdict isinsufficient data: not a green light, not a red one. A few pairs earn a real answer — some are routinely sold and mixed as blends, a few have a named chemical reason to stay apart. Here's every pairing, with the reasoning shown for each cell.
Can these share a syringe?
Pick two or more compounds. You'll get the physical-compatibility verdict, the single pair that drives it, its evidence, and an honest read on what's simply unstudied.
01 How to read
How to read this
"Compatible" here means one narrow thing: can these two molecules physically share a vial without one wrecking the other — no denaturing (proteins unravelling), precipitating (clumping out of solution), or oxidizing (chemically breaking down). It says nothing about whether the stack is a smart idea for a person. That's a separate question, and this tool doesn't answer it.
Six honest categories, and most of the grid sits in the least glamorous one — insufficient data:
- Co-formulated in practiceSold as a single-vial blend and/or routinely co-reconstituted; compatible diluent and pH, no known chemical interaction. Physically compatible — not a recommendation to combine.
- Chemically plausible, community-reportedCommunity combines them; they share a diluent and carry no reactive-residue or metal conflict — but this is not a manufactured blend or a stability study. Anecdotal, n = community.
- Insufficient dataNo compatibility study, no established co-formulation, no specific incompatibility identified. This is the honest default for most pairs — general sterility principles apply; when unsure, keep them in separate syringes.
- Different diluent / pHA physical mismatch — one needs a different diluent, or their stable-pH windows do not overlap — so a single compromise pH risks precipitation or degradation. People may still stack them as separate injections.
- Avoid — named incompatibilityA specific, named mechanism makes co-mixing degrade, precipitate, or inactivate one of them — acidic-formulation denaturation, or metal-catalyzed oxidation of a partner carrying methionine, cysteine, or tryptophan.
- Administered soloDelivered in its own device or dedicated formulation and used on its own. Combining is a pharmacology question, not a syringe-chemistry one — there is no co-injection compatibility to report.
02 The matrix
The compatibility matrix
28 compounds, every possible pair resolved. Of 378 pairings,245 are genuinely unstudied — the flat "insufficient data" default —0 involve a compound that's only ever given on its own, and just 89have a specific, sourced reason to say anything more. That lopsided ratio is the whole point: we don't invent certainty the research doesn't have.
| ↓ rowcolumn → | AOD-9604 | Insulin | BPC-157 | KPV | Pentadeca Arginate | TB-500 | Thymosin Beta-4 | VIP | CJC-1295 (no DAC) | GHRP-2 | GHRP-6 | Hexarelin | IGF-1 LR3 | Ipamorelin | Modified GRF 1-29 | Sermorelin | Tesamorelin | Epitalon | FOXO4-DRI | GDF-11 | MOTS-c | NAD+ | LL-37 | Thymosin Alpha-1 | Melanotan II | Melanotan II | DSIP | GHK-Cu |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AOD-9604Metabolic (injectable) | ||||||||||||||||||||||||||||
| InsulinMetabolic (injectable) | ||||||||||||||||||||||||||||
| BPC-157Healing / recovery | ||||||||||||||||||||||||||||
| KPVHealing / recovery | ||||||||||||||||||||||||||||
| Pentadeca ArginateHealing / recovery | ||||||||||||||||||||||||||||
| TB-500Healing / recovery | ||||||||||||||||||||||||||||
| Thymosin Beta-4Healing / recovery | ||||||||||||||||||||||||||||
| VIPHealing / recovery | ||||||||||||||||||||||||||||
| CJC-1295 (no DAC)GH secretagogues | ||||||||||||||||||||||||||||
| GHRP-2GH secretagogues | ||||||||||||||||||||||||||||
| GHRP-6GH secretagogues | ||||||||||||||||||||||||||||
| HexarelinGH secretagogues | ||||||||||||||||||||||||||||
| IGF-1 LR3GH secretagogues | ||||||||||||||||||||||||||||
| IpamorelinGH secretagogues | ||||||||||||||||||||||||||||
| Modified GRF 1-29GH secretagogues | ||||||||||||||||||||||||||||
| SermorelinGH secretagogues | ||||||||||||||||||||||||||||
| TesamorelinGH secretagogues | ||||||||||||||||||||||||||||
| EpitalonLongevity | ||||||||||||||||||||||||||||
| FOXO4-DRILongevity | ||||||||||||||||||||||||||||
| GDF-11Longevity | ||||||||||||||||||||||||||||
| MOTS-cLongevity | ||||||||||||||||||||||||||||
| NAD+Longevity | ||||||||||||||||||||||||||||
| LL-37Immune / antimicrobial | ||||||||||||||||||||||||||||
| Thymosin Alpha-1Immune / antimicrobial | ||||||||||||||||||||||||||||
| Melanotan IIMelanocortin | ||||||||||||||||||||||||||||
| Melanotan IIMelanocortin | ||||||||||||||||||||||||||||
| DSIPNootropic | ||||||||||||||||||||||||||||
| GHK-CuCosmetic |
Hover, tap, or keyboard-focus any cell for the reasoning and its evidence. Tap a cell to pin it. On the legend above, toggle a category to filter the grid.
03 The findings
The pairs we can actually say something about
Commonly combined & chemically plausible
These are the pairs with an actual basis for going into one syringe — either sold as ready-made blends or backed by shared chemistry. The evidence badge on each one keeps us honest: most of this is community practice and formulation know-how, not a controlled trial.
- BPC-157 + TB-500Co-formulated in practiceAnecdotal
BPC-157 and TB-500 are widely co-reconstituted and sold as pre-mixed blends. Both are described as stable in bacteriostatic water around pH 5–7, and neither carries cysteine or methionine, so the disulfide-crosslinking and metal-oxidation pathways that make some pairs incompatible simply do not apply here. One caveat: BPC-157 is sometimes reconstituted in dilute acetic acid for stability — if you take that route, it no longer shares a diluent with TB-500, which pushes the pair toward "different diluent / pH." Combined in bacteriostatic water, they are physically compatible; that is not a recommendation to stack them.
- BPC-157 + GHK-CuChemically plausible, community-reportedMechanistic
BPC-157 and GHK-Cu are combined in the community "GLOW" blend, and the common fear — "the copper in GHK-Cu oxidizes everything" — does not apply here. Copper catalyzes oxidation specifically of methionine, cysteine, and tryptophan, and BPC-157 (GEPPPGKPADDAGLV) contains none of those residues. So the pathway people worry about is chemically absent for this exact pair. That is a checkable reason the blend is not self-destructing — not a green light to inject it. We hold it at "chemically plausible" because it rests on residue chemistry, not a stability study.
- TB-500 + GHK-CuChemically plausible, community-reportedMechanistic
GHK-Cu and TB-500 are the other half of the community "GLOW" blend, and the same honest chemistry applies: copper-catalyzed oxidation targets methionine, cysteine, and tryptophan, and the commonly-sold TB-500 fragment carries none of them. With no target residue present, the copper has nothing to oxidize on this partner, so the pathway people fear is absent for this pair. We keep it at "chemically plausible" — this reasoning is residue chemistry, not a measured stability study of the blend.
- CJC-1295 (no DAC) + GHRP-2Chemically plausible, community-reportedAnecdotal
CJC-1295 (no DAC) and GHRP-2 follow the same growth-hormone-secretagogue logic as the CJC/ipamorelin blend — a GHRH analog paired with a ghrelin-receptor agonist, same bacteriostatic-water diluent, long-standing combined use. It is less "productized" than CJC/ipamorelin, so we hold it a step back: chemically plausible and community-reported, not an established manufactured blend. One real nuance — GHRP-2 carries tryptophan, an oxidation-sensitive residue, so avoid co-mixing it with a copper carrier like GHK-Cu in the same draw.
- CJC-1295 (no DAC) + GHRP-6Chemically plausible, community-reportedAnecdotal
CJC-1295 (no DAC) and GHRP-6 pair a GHRH analog with a ghrelin-receptor agonist — the same growth-hormone-secretagogue combination people have run together for years, in the same bacteriostatic-water diluent. We keep it at "chemically plausible, community-reported" rather than a manufactured blend. Note that GHRP-6 carries two tryptophan residues (oxidation-sensitive), so it should not share a draw with a copper carrier such as GHK-Cu.
- CJC-1295 (no DAC) + IpamorelinCo-formulated in practiceAnecdotal
CJC-1295 (no DAC) and ipamorelin are the most commonly co-formulated peptide pair — compounding pharmacies routinely put both in one vial (typically ~1:1) and the community draws them together in one syringe. They hit different receptors (a GHRH analog plus a ghrelin-receptor agonist), share the same bacteriostatic-water diluent, and carry no shared reactive residue that would react across the two. This is real-world practice plus compatible chemistry — not a controlled stability study, and not a recommendation to inject them.
Named reasons to keep apart
A red verdict has to name a mechanism — never a vibe, never guilt by association. When one shows up here, it's because there's a specific chemical reason these two shouldn't share a vial.
- AOD-9604 + GHK-CuAvoid — metal-catalyzed oxidation
GHK-Cu carries a redox-active metal (copper), which can catalyze oxidation of AOD-9604's oxidation-sensitive residues (Cys). That is a named degradation pathway, so keep them in separate syringes.
- GHK-Cu + InsulinAvoid — metal-catalyzed oxidation
Insulin is formulated acidic (about pH 4). Drawing GHK-Cu — formulated for near-neutral pH — into that low pH can denature or precipitate it. This is the documented class of insulin/pramlintide incompatibility, not a preference call.
- GHK-Cu + Thymosin Beta-4Avoid — metal-catalyzed oxidation
GHK-Cu carries a redox-active metal (copper), which can catalyze oxidation of Thymosin Beta-4's oxidation-sensitive residues (Met). That is a named degradation pathway, so keep them in separate syringes.
- GHK-Cu + VIPAvoid — metal-catalyzed oxidation
GHK-Cu carries a redox-active metal (copper), which can catalyze oxidation of VIP's oxidation-sensitive residues (Met). That is a named degradation pathway, so keep them in separate syringes.
- GHK-Cu + GHRP-2Avoid — metal-catalyzed oxidation
GHK-Cu carries a redox-active metal (copper), which can catalyze oxidation of GHRP-2's oxidation-sensitive residues (Trp). That is a named degradation pathway, so keep them in separate syringes.
- GHK-Cu + GHRP-6Avoid — metal-catalyzed oxidation
GHK-Cu carries a redox-active metal (copper), which can catalyze oxidation of GHRP-6's oxidation-sensitive residues (Trp). That is a named degradation pathway, so keep them in separate syringes.
- GHK-Cu + HexarelinAvoid — metal-catalyzed oxidation
GHK-Cu carries a redox-active metal (copper), which can catalyze oxidation of Hexarelin's oxidation-sensitive residues (Trp). That is a named degradation pathway, so keep them in separate syringes.
- GHK-Cu + IGF-1 LR3Avoid — metal-catalyzed oxidation
IGF-1 LR3 is formulated acidic (about pH 4). Drawing GHK-Cu — formulated for near-neutral pH — into that low pH can denature or precipitate it. This is the documented class of insulin/pramlintide incompatibility, not a preference call.
- GHK-Cu + SermorelinAvoid — metal-catalyzed oxidation
GHK-Cu carries a redox-active metal (copper), which can catalyze oxidation of Sermorelin's oxidation-sensitive residues (Met). That is a named degradation pathway, so keep them in separate syringes.
- FOXO4-DRI + GHK-CuAvoid — metal-catalyzed oxidation
GHK-Cu carries a redox-active metal (copper), which can catalyze oxidation of FOXO4-DRI's oxidation-sensitive residues (Trp). That is a named degradation pathway, so keep them in separate syringes.
- GHK-Cu + MOTS-cAvoid — metal-catalyzed oxidation
GHK-Cu carries a redox-active metal (copper), which can catalyze oxidation of MOTS-c's oxidation-sensitive residues (Met, Trp). That is a named degradation pathway, so keep them in separate syringes.
- GHK-Cu + Melanotan IIAvoid — metal-catalyzed oxidation
GHK-Cu carries a redox-active metal (copper), which can catalyze oxidation of Melanotan II's oxidation-sensitive residues (Trp). That is a named degradation pathway, so keep them in separate syringes.
- GHK-Cu + Melanotan IIAvoid — metal-catalyzed oxidation
GHK-Cu carries a redox-active metal (copper), which can catalyze oxidation of Melanotan II's oxidation-sensitive residues (Trp). That is a named degradation pathway, so keep them in separate syringes.
- DSIP + GHK-CuAvoid — metal-catalyzed oxidation
GHK-Cu carries a redox-active metal (copper), which can catalyze oxidation of DSIP's oxidation-sensitive residues (Trp). That is a named degradation pathway, so keep them in separate syringes.
The class rules that drive the rest of the grid
Three chemistry rules — not one-off judgment calls — do most of the work on the non-default cells. Each is applied the same way to every pair, so nothing here is cherry-picked.
- Insulin is acidic — treat it as an "avoid" with neutral-pH peptides.Insulin is formulated at about pH 4. Draw a peptide built for near-neutral pH into that acid and it can unravel or clump out of solution. So insulin is an avoid with every neutral-pH peptide here (23 pairs) — the same class of problem the pramlintide label spells out.
- Pramlintide is acidic too — a diluent / pH mismatch with neutral peptides.Its acidic formulation doesn't share a diluent — the sterile liquid a peptide is mixed into — with the neutral-pH peptides, so those pairings (46) land in "different diluent / pH — not typically combined." Its one flat "do not mix" is with insulin, and that one's documented right on the drug label.
- The GLP-1s ride solo.Cagrilintide, CagriSema, Dulaglutide, Exenatide, Liraglutide, Mazdutide, Orforglipron, Retatrutide, Semaglutide, Survodutide, Tirzepatide, Larazotide, MK-677, SS-31 (elamipretide), Melanotan I, PT-141, Setmelanotide, Cerebrolysin, Noopept, Selank, Semax, Tesofensine, Argireline, Matrixyl, Melitane, Palmitoyl Tripeptide-1, SNAP-8, Syn-Ake, Pramlintide arrive in their own pens and pre-set formulations, so there's no co-injection question to answer — every pairing that involves one (0 of them) is marked "administered solo."
Everything else: insufficient data, on purpose
The remaining 245 pairings are the honest default, and it means exactly what it says: nobody has published whether those two hold up together in one vial. That's not a quiet "probably fine" — it's a genuine blank. General sterility rules still apply, and when you're unsure, the safe move is to keep them in separate syringes. We'll upgrade a cell the moment there's a real, sourced reason to — and not one minute before.
04 Sterility & stability
Sterility & stability — what actually matters at home
These aren't scare-warnings — they're the useful part. If you're going to combine anything, this is the reality worth keeping in your head before you draw anything up.
- "Compatible" is physical, not an endorsement. A green cell means the two molecules can plausibly share a vial without wrecking each other. It does not mean the stack is wise, effective, or right for you.
- Most of this is genuinely unstudied. For most pairs, "insufficient data" is the real answer — no one has tested them together, so general sterility principles are all you have to go on.
- Every extra compound in one draw multiplies contamination risk.Each vial you puncture and each transfer you make is another way in for microbes — all of it concentrated into a single injection.
- Once mixed, shelf life is largely unknown. A blend's stability isn't simply the shorter of its two parts — it can be worse if the compounds react with each other. Without data on that specific blend, use the shorter, more cautious window.
- Cloudiness, color change, or floating particles: discard it.Those are the visible signs of precipitation — the compound clumping out of solution, usually from a pH or aggregation failure. It's the single most useful at-home check, so do it before every use.
- A diluent mismatch is a real "don't." If one compound needs an acidic liquid and the other needs a neutral one, combining them isn't a matter of preference — it compromises both.
How we grade a verdict: the same evidence tiers we use everywhere else on the site. A "commonly combined" green that rests only on community practice gets labeledanecdotal; a verdict argued from chemistry is mechanistic; a documented, label-level incompatibility is stronger still. The badge always travels with the verdict, so you can see exactly how much weight it carries —how we grade evidence.